BRAF and melanoma: In 2011, Carl June’s successful application of CAR-T cell therapy for leukemia treatment marked a significant step forward in immunotherapy.14 The 2014 FDA approval of Pembrolizumab and Nivolumab for the treatment of melanoma, along with the accelerated approval of Trametinib and Dabrafenib for patients with BRAF-mutant melanoma, marked a new beginning in cancer immunotherapy.15–17 Preventive measures also advanced, with the approval of the nine-valent Gardasil 9 vaccine in December 2014,18 offering broader protection against HPV strains associated with cervical cancer.